Viral macrophage inflammatory protein 2; Viral macrophage inflammatory protein II; vMIP-II
Purity
>97% by SDS-PAGE and HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0μg-10.0μg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB, pH7.4, 150mM NaCl.
Endotoxin
Less than 1EU/μg of rViMIP-2 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Chemokines
Background
Viral MIP-2 is one of the three chemokine-like proteins expressed by the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV) and the other is ViMIP-1 and ViMIP-3. It shares 41% and 48% with human MIP-1α and ViMIP-1, respectively. ViMIP-2 has been shown to have antagonist activity towards a wide range of chemokine receptors and has functions of blocking infection by several different human immunodeficiency virus type 1 (HIV-1) strains. It may form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. Additionally, ViMIP-2 has been shown to activate and chemoattract human eosinphils.